Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic